Arthur Caplan on the ethical responsibilities of the longevity field and the societal impact of emerging interventions.
Dr Arthur Caplan, a leading bioethicist and founding head of the Division of Medical Ethics at NYU School of Medicine in New York City, is one of the most influential voices in medical ethics today. With a career spanning decades, his work has shaped global discussions on transparency, fairness and responsibility in biomedical research. At the Global Healthspan Summit (GHS2025) in Riyadh tomorrow, he will join Dr Salman AlAsiry for a timely discussion titled Ethics Focus: Equitable Approaches to Geroscience – How Can We Balance Ethics and Justice? This session will address the pressing ethical challenges in longevity science; as geroscience advances, ensuring equitable access to its benefits remains a central concern – one that demands both thoughtful discourse and impactful policy action.
The session will explore the ethical, social and economic dimensions of funding geroscience research, emphasizing fairness in the distribution of its breakthroughs. With global aging accelerating, interventions targeting the biological mechanisms of aging could transform healthspan, but they also raise concerns about accessibility, affordability and the prioritization of resources. By examining frameworks such as egalitarianism and sufficientarianism, the discussion will highlight the complexities of ensuring longevity innovations serve all populations – not just the privileged few. This is part of Hevolution’s ethos, and we are likely to see it referenced throughout the Summit.
Longevity.Technology: GHS2025 reflects Hevolution Foundation’s commitment to not only accelerating geroscience research but also fostering ethical accountability in its implementation. Through panels like this, the summit creates a platform for interdisciplinary dialogue, bringing together policymakers, researchers and industry leaders to confront the ethical dilemmas that arise with groundbreaking innovation. Ahead of the panel, we spoke with Dr Caplan about the ethical challenges in healthspan research, including equitable access, transparency in gene therapy, the societal impact of weight-loss drugs and the need for rigorous safety measures in longevity interventions.
It is clear that addressing ethical considerations in healthspan extension research is a key focus for the Summit as Caplan explains.
“The Summit has many sessions devoted to ethics including a session with a student winner of the Foundation’s annual best ethics paper,” he says. “This sends the loud message that ethics counts and that the field of aging must commit to just distribution of its findings for all humanity and to adhere to ethical guidelines in conducting geroscience research that likely involves children and young persons.”
Events like GHS2025 help to foster dialogue about areas like bioethics and these conversations need to run in parallel with research rather than trying to shut the lab door after the clinical trial has bolted. Transparency is key, and in his recent commentary on gene therapy trials, Caplan emphasized the need for Caplan stressed the need for clear and open communication.
“Early Gene Therapy (GT) trials generally proceed in accordance with a rubric established decades ago for small molecule development which privileges commercial secrecy,” he explains, adding that while largely methodologically sound, several facets of that rubric are problematic in the context of GTs. “Unlike small molecules, GTs require immunosuppression, and cannot be turned up, turned down, turned off, or re-dosed. Similarly, because the majority of GTs rely on a viral vector-based delivery system, they are far more related to each other creating cross trial relevance than do the myriad small molecules in development across thousands of disparate diseases.”
Caplan says that these characteristics escalate the need for more transparency for clinical investigators, ethics committees and data safety monitoring committees across all investigations using the same or similar vectors, vector serotypes, routes of administration, vector genome doses, immunosuppression and rescue methods for acute reactions to early GTs, should they occur. “Strict trade secrecy protections which prohibit regulatory agencies from sharing potentially relevant safety or other details established during the era of small molecule development are obsolete and dangerous in the context of these between-GT program similarities,” he says.
There is a path to be navigated between rapid medical innovation and the ethical necessity for thorough testing, especially in the context of aging interventions. Caplan says that striking the right balance between progress and precaution is essential.
“Anti-aging drugs require both rigorous clinical trials in diverse populations as well as systematic follow up using transparent registries,” he explains. “Widespread use, cost and exposure to children require the best safety and efficacy evidence.”
There has been much discussion around popular weight-loss drugs like Ozempic, and Caplan points out that despite huge and ongoing enthusiasm in the US and worldwide for using injectable drugs to treat diabetes, heart disease and obesity, there are ethical concerns to take into account.
“There are many ethical considerations that need to be acknowledged and debated about a future in which drugs are used to prevent and control weight,” he explains. “These include enormous cost, counterfeit marketing, the possibility of mandatory imposed use, impact on the environment of waste from shots, long term risks and the acceptability of dependency – a life on a drug that may discourage lifestyle and diet change in favor of staying on drugs.”
To watch the Global Healthspan Summit live on Feb 4-5, please go to: www.hevolution.com
